ArticleJournal of thoracic disease2025
The outcomes of neoadjuvant immunotherapy combined with antiangiogenic therapy versus chemoimmunotherapy in resectable non-small cell lung cancer: a propensity score matching analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Platinum-based chemotherapy is the most common combination regimen with immune checkpoint inhibitors (ICIs) in neoadjuvant therapy for resectable non-small cell lung cancer (NSCLC), yet the multimodal strategies of neoadjuvant therapy have not been fully explored. Antiangiogenic therapy is known to modify the tumor immune microenvironment, making it a potential candidate. This study aimed to explore the pathological and survival outcomes of neoadjuvant immunotherapy (IO) combined with antiangiogenic therapy and compare the outcomes with neoadjuvant chemoimmunotherapy (IO + CT) in resectable NSCLC. Methods: The clinical and pathological characteristics of NSCLC patients who underwent neoadjuvant immunotherapy plus antiangiogenic therapy (IO + AA) or IO + CT before radical surgery at a high-volume single center between December 2019 and June 2024 were retrospectively collected. The IO + CT group was matched 4:1 with the IO + AA group by propensity score matching (PSM). The surgical and survival outcomes were systematically collected and analyzed. Results: During a nearly 6-year study period, the majority of patients (411 of 431, 95.4%) underwent neoadjuvant IO + CT, while 20 patients (4.6%) underwent neoadjuvant IO + AA. Following PSM, the major pathological response (MPR) was comparable between the two groups (66.7% Conclusions: This finding suggests that neoadjuvant IO + AA demonstrates no superiority over neoadjuvant IO + CT in terms of pathological and survival outcomes. Although it may serve as a chemo-free alternative for selective patients, the current evidence supports IO + CT as the standard neoadjuvant strategy in resectable NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.